Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04598009 · ClinicalTrials.gov registry record · Phase 2
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
A Phase 2 study of Melanoma Stage IV and Melanoma Stage III, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT04598009: Recruiting Phase 2 study of Melanoma Stage IV and Melanoma Stage III, sponsored by University of California, San Francisco.
NCT04598009 is a Phase 2 study of Melanoma Stage IV and Melanoma Stage III that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 25 participants, below the 101-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04598009, a Phase 2 study of Melanoma Stage IV and Melanoma Stage III, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.
Primary Outcome
Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the null hypothesis at each stage will use the method of Koyama \& Chen and 90% confidence interval will be reported.
Conditions Studied
Interventions
- DRUG Binimetinib
- DRUG Imatinib
Study Locations (2)
California
- UC San Diego Moores Cancer Center - La Jolla
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
What NCT04598009 shows while recruiting
NCT04598009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 101-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Melanoma Stage IV appearing as the primary indexed condition, and to 2 interventions - of which Binimetinib is the first listed.
NCT04598009 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04598009 about?
NCT04598009 is a clinical study titled "Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma". This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving b...
What is the current status of trial NCT04598009?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-03-03. Estimated completion is 2027-05-31.
What conditions does trial NCT04598009 study?
This clinical trial studies the following conditions: Melanoma Stage IV, Melanoma Stage III.
What interventions are being tested in trial NCT04598009?
The interventions under investigation include: Binimetinib (DRUG), Imatinib (DRUG).
Who is sponsoring clinical trial NCT04598009?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04598009 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04598009's enrollment target sits among peer trials
25 16th of 17 higher than 2 of 17 other Melanoma Stage IV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma Stage IV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
RECRUITING · Phase 2
-
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI